deep dives into generic leaders—such as Teva, Sandoz, and Viatris—and more. Download the report to learn how to leverage these top companies’ growth plans for your investing strategy.

Snap's DAU growth has stabilized and is expected to rise 8.7% YoY in 1Q FY2025. Read what makes SNAP stock's recent sell-off ...

InvestingPro data reveals multiple additional growth indicators and financial metrics that could impact your investment decision - unlock these insights with a subscription. The generic drug ...